5-羟色氨酸对静止期炎症性肠病疲劳的影响:一项随机对照试验
在13家比利时医院开展的多中心随机对照交叉试验,纳入166例静止期但伴疲劳(疲劳视觉模拟量表评分≥5)的炎症性肠病患者,交叉接受口服5-羟色氨酸100 mg或安慰剂每日两次、连续2个8周周期。结果显示5-羟色氨酸虽显著提高血清5-羟色氨酸和5-羟色胺水平,但疲劳视觉模拟量表≥20%改善比例在安慰剂组为37.6%、5-羟色氨酸组为35.6%(P = .830),差异无统计学意义。
要点
- 5-羟色氨酸100 mg每日两次未较安慰剂更有效改善静止期炎症性肠病患者的疲劳。
- 疲劳视觉模拟量表≥20%改善比例:安慰剂组37.6% vs 5-羟色氨酸组35.6%(P = .830)。
- 血清5-羟色氨酸和5-羟色胺水平在5-羟色氨酸治疗期间显著升高。
核心结论
- 尽管血清5-羟色氨酸和5-羟色胺水平显著升高,口服5-羟色氨酸对炎症性肠病相关疲劳的改善并未优于安慰剂。
研究设计与样本
- 在13家比利时医院开展的多中心随机对照试验,采用交叉设计,纳入166例处于缓解期但伴疲劳(疲劳视觉模拟量表评分≥5)的炎症性肠病患者。
- 患者交叉接受口服5-羟色氨酸100 mg或安慰剂每日两次,连续2个8周周期。
主要发现
- 5-羟色氨酸治疗期间血清5-羟色氨酸较安慰剂显著升高(估计平均差值52.66 ng/mL;95% CI 39.34-65.98 ng/mL;P < .001)。
- 5-羟色氨酸治疗期间血清5-羟色胺较安慰剂显著升高(估计平均差值3.0 ng/mL;95% CI 1.97-4.03 ng/mL;P < .001)。
- 疲劳视觉模拟量表≥20%改善比例在安慰剂组为37.6%、5-羟色氨酸组为35.6%(P = .830)。
- 疲劳视觉模拟量表评分变化在5-羟色氨酸与安慰剂之间相当(-0.18;95% CI -0.81至0.46;P = .581)。
- 慢性病治疗功能评估疲劳量表评分变化在5-羟色氨酸与安慰剂之间相当(0.68;95% CI -2.37至3.73;P = .660),抑郁、焦虑和压力评分变化亦相当。
关键数值与推荐
- 疲劳纳入标准为疲劳视觉模拟量表评分≥5。
- 5-羟色氨酸给药方案为口服100 mg每日两次,每个周期8周,共2个周期。
- 主要终点为干预8周后疲劳视觉模拟量表评分较基线降低≥20%的患者比例。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Fatigue is highly prevalent among patients with inflammatory bowel disease (IBD), and only limited treatment options are available. Based on the hypothetical link between low serum tryptophan concentrations and fatigue, we determined the effect of 5-hydroxytryptophan supplementation on fatigue in patients with inactive IBD. METHODS: A multicenter randomized controlled trial was performed at 13 Belgian hospitals, including 166 patients with IBD in remission but experiencing fatigue, defined by a fatigue visual analog scale (fVAS) score of ≥5. Patients were treated in a crossover manner with 100 mg oral 5-hydroxytryptophan or placebo twice daily for 2 consecutive periods of 8 weeks. The primary end point was the proportion of patients reaching a ≥20% reduction in fVAS after 8 weeks of intervention. Secondary outcomes included changes in serum tryptophan metabolites, Functional Assessment of Chronic Illness Therapy Fatigue scale, and scores for depression, anxiety, and stress. The effect of the intervention on the outcomes was evaluated by linear mixed modeling. RESULTS: During 5-hydroxytryptophan treatment, a significant increase in serum 5-hydroxytryptophan (estimated mean difference, 52.66 ng/mL; 95% confidence interval [CI], 39.34-65.98 ng/mL; P < .001) and serotonin (3.0 ng/mL; 95 CI, 1.97-4.03 ng/mL; P < .001) levels was observed compared with placebo. The proportion of patients reaching ≥20% reduction in fVAS was similar in placebo- (37.6%) and 5-hydroxytryptophan (35.6%)-treated patients (P = .830). The fVAS reduction (-0.18; 95% CI, -0.81 to 0.46; P = .581) and Functional Assessment of Chronic Illness Therapy Fatigue scale increase (0.68; 95% CI, -2.37 to 3.73; P = .660) were both comparable between 5-hydroxytryptophan and placebo treatment as well as changes in depression, anxiety, and stress scores. CONCLUSIONS: Despite a significant increase in serum 5-hydroxytryptophan and serotonin levels, oral 5-hydroxytryptophan did not modulate IBD-related fatigue better than placebo. (Trial Registration: Belgian Federal Agency for Medication and Health Products, EudraCT number: 2017-005059-10 and ClinicalTrials.gov: NCT03574948, https://clinicaltrials.gov/ct2/show/NCT03574948.).
引用
- Truyens M, Lobatón T, Ferrante M, et al. Effect of 5-Hydroxytryptophan on Fatigue in Quiescent Inflammatory Bowel Disease: A Randomized Controlled Trial. Gastroenterology. 2022. PMID: 35940251. doi:10.1053/j.gastro.2022.07.052
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。